BHI Weekly News Archives Archives - Page 29 of 62 - BioHealth Innovation

346th Edition – March 19, 2019

By adminBHI Weekly News Archives

BioHealth Innovation

If you are having trouble viewing this email, please click here

March 19, 2019

FOUNDING MEMBER OF

Anne Lindblad, Ph.D., President, and CEO of Emmes, joins Rich Bendis for BioTalk

BioTalk Host Rich Bendis sits down with Anne Lindblad, Ph.D., President, and CEO of Emmes, to discuss her view of the region, her history with the company, and their mission, vision, and values.

Anne Lindblad, Ph.D., joined Emmes in 1982 as a Biostatistician and is currently the President and CEO. She has supported clinical research throughout her career, serving as Principal Investigator of projects spanning diverse disease areas, including neurology, ophthalmology, oncology, dialysis, transplantation, speech and hearing, and dentistry. Dr. Lindblad has been an NIH reviewer on multiple project applications for NINDS, NEI, NICHD, NIDCR, NIDDK, and NCCAM and has served as a member or chair of several Data and Safety Monitoring Committees for NEI, NIAAA, NIDDK, and NINDS. She was a member of an Advisory Committee charged with drafting policy to shape the appropriate planning and conduct of intramural studies at NIH. She was elected to the Board of Directors for the Society for Clinical Trials (2003-2006) and served as Program Chair (2002), as an Officer (2006-2014), and as President (2012-2013). Dr. Lindblad was selected to serve on NIH’s National Advisory Dental and Craniofacial Research Council from 2004 through 2008. She has taught courses in best practices in clinical trial design and conduct for ophthalmologists, neurologists, and immunologists. She has published and presented over 100 manuscripts in peer-reviewed journals and conferences. Dr. Lindblad joined the Board of BioHealth Innovation in 2018. Emmes has grown from 15 employees in 1982 to over 650 globally. In 2019 Emmes announced a significant investment by Behrman Capital which will allow Emmes to gain access to new tools, talent, service offerings, and expanded footprint faster than what Emmes might otherwise have accomplished.

Listen now on iTunes, Google Play, and TuneIn.

2019 Fifth Annual BioHealth Capital Region Forum…Great Speakers and Networking…Register Today!

April 8 + 9, 2019

One MedImmune Way, Gaithersburg, MD 20878

This invitation-only event is free for executive level biotech leaders and is presented by BioHealth Innovation, VirginiaBio, Maryland Tech Council, University System of Maryland, Children’s National Health Network, HemoShear, GSK, BeneVir, Quality Biological, Johns Hopkins University and AstraZeneca. Maryland, Virginia, and Washington, DC set the bar high for biotech innovation. So please join us for our Annual BioHealth Capital Region Forum that will highlight the accomplishments of today and chart our successes of tomorrow.

REGISTER TODAY!

Register at bhcrf2019.eventbrite.com

For more information about our speakers and event schedule, please visit www.bhcrforum.com.

Osiris to be acquired by British medical device company for $660.5M – Baltimore Business Journal

Columbia-based Osiris is coming off a tumultuous three-year period in which four CEOs left the company and several former executives faced criminal charges for fraud.

We’re not doing enough for our kids | Kurt Newman | TEDxTysons – YouTube

It all begins at birth. That’s the starting point for Kurt Newman as he shares his poignant journey as a pediatric surgeon. Newman offers a new perspective for approaching the most chronic and debilitating health conditions. Against a backdrop of personal challenges and patients who overcame impossible odds, we learn to appreciate the importance of treating every child with early customized care, and an eye for the future.

Built For Bio: Greg Merril, CEO of Adaptive Phage Therapeutics — MCEDC

MCEDC discovers how Greg’s clinical-stage company in Montgomery County, MD is using bacteria phage to combat the worldwide crisis in multi-drug resistant bacterial infections.

New Study Shows Bayh-Dole is Working as Intended

Just as the drug pricing debate on Capitol Hill is heating up, an important new study, “The Bayh-Dole Act’s Vital Importance to the U.S. Life-Sciences Innovation System,” published by the Information Technology & Innovation Foundation (ITIF), underscores the law’s contribution to the United States’ lead in the life sciences. The report warns that attempts to misuse the march-in rights provision of the law to control drug prices would have serious consequences to our competitiveness and our health.

Successful Marketing & PR Strategies for Your Startup (4/4)

PR and Marketing – What’s the difference?
How do you establish your brand?
Are their tips for marketing on a tight budget?
What should an effective marketing plan include?
How can a strong digital strategy build credibility?
How can I get press coverage for my product/service/technology?
What type of budget is realistic for marketing/public relations activities?

Learn the answers to these questions and more through the April 4th PathFinder Innovation Program. (There is no charge to attend in person or by videoconference, however, pre-registration by NOON, 4/2 is required).

8:15 a.m. Networking and Coffee8:30 a.m. – Issues Overview and Discussion (in person/by videoconference)

Pam Clark, Principal, Creative Director – Clark Concepts
Warren Ellis, VP of Marketing, Montgomery County Economic Development Corp.
Rachel Wojnilower, Digital Marketing Manager – Clark Concepts
Jennifer Owers, WebDesigner/Project Manager – Clark Concepts

9:45 a.m. – 1:1 Office Hours (in person/by videoconference)*

This program is cosponsored by BioHealth Innovation, Launch Workplaces, and TEDCO. It is open to anyone in the BioHealth Capital Region.

To register/for more information, email: BHI@BioHealthInnovation. (Please include in your RSVP: Your company name, your title and contact information, the type of product(s) services you are promoting, and your interest in a 1:1 meeting following the overview session.)

*Attendance at Overview in person/by videoconference is required to participate in 1:1 sessions.

BioHealth Capital Region is Entering Period of “Creative Destruction” at Perfect Time · BioBuzz

In 1942, Austrian economist Joseph Schumpeter wrote, “ …industrial mutation—if I may use that biological term—that incessantly revolutionizes the economic structure from within, incessantly destroying the old one, incessantly creating a new one. This process of Creative Destruction is the essential fact about capitalism.”

The Universities at Shady Grove April 6 Expo Targets Potential Undergraduates | Montgomery Community Media

The Universities at Shady Grove (USG) will hold a Undergraduate Expo Saturday, Apr. 6 from 9 a.m. to noon. USG is part of the University System of Maryland and offers approximately 80 undergraduate and graduate degree programs from nine different state universities on the Rockville campus.

Alexandria Real Estate Equities, Inc. Announces Pricing of Public Offering of $200,000,000 of Senior Notes due 2024, $350,000,000 of Senior Notes due 2026 and $300,000,000 of Senior Notes due 2049

Alexandria Real Estate Equities, Inc. (“Alexandria” or the “Company”) (NYSE: ARE) today announced that it has priced a public offering of $200,000,000 aggregate principal amount of 4.000% senior notes due 2024, $350,000,000 aggregate principal amount of 3.800% senior notes due 2026 and $300,000,000 aggregate principal amount of 4.850% senior notes due 2049. Goldman Sachs & Co. LLC, Citigroup Global Markets Inc., J.P. Morgan Securities LLC and SMBC Nikko Securities America, Inc. are acting as joint book-running managers in connection with the public offering and Barclays Capital Inc., BB&T Capital Markets, a division of BB&T Securities, LLC, BBVA Securities Inc., BNP Paribas Securities Corp., Capital One Securities, Inc., Evercore Group L.L.C., Fifth Third Securities, Inc., Mizuho Securities USA LLC, PNC Capital Markets LLC, RBC Capital Markets, LLC, Regions Securities LLC, Samuel A. Ramirez & Company, Inc., Scotia Capital (USA) Inc., SunTrust Robinson Humphrey, Inc., TD Securities (USA) LLC, U.S. Bancorp Investments, Inc. and Wells Fargo Securities, LLC are acting as co‑managers in connection with the public offering.

Personal Genome Diagnostics CE Marks Liquid Biopsy Test | BioSpace

Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced that it has applied the CE mark to PGDx elio™ plasma resolve. It is the first kitted plasma-based NGS oncology test to have that certification, enabling greater access to genomic testing for cancer patients in Europe.

Sonavex readies to launch sales of medical tech with new FDA clearance – Baltimore Business Journal

Sonavex is first targeting the reconstructive surgery market with its new medical technology, which just earned its final FDA clearance.

LifeBridge Health and CareFirst are hosting an ‘innovation challenge’ for digital health startups – Technical.ly Baltimore

A pair of Baltimore healthcare leaders are partnering to reach digital health startups.

Hospital network LifeBridge Health and health insurance provider CareFirst BlueCross Blue Shield will be hosting an innovation challenge that includes a chance to pitch and win funding for companies.

Biopharma breathes ‘sigh of relief’ with HHS’ interim FDA appointment: analyst | FiercePharma

It didn’t take long for the Trump administration to tap Ned Sharpless, now director of the National Cancer Institute, to take the reins at FDA for now—or for biopharma to hail the news. In fact, one team of analysts said the industry would “breathe a collective sigh of relief.”

How Eargo Is Destigmatizing Hearing Loss Through Innovation

Eargo, a direct-to-consumer health technology company that is destigmatizing hearing loss through innovation, announced it raised $52 million in Series D funding from existing investors New Enterprise Associates (NEA), the Charles and Helen Schwab Foundation, Nan Fung Life Sciences, and Maveron. And new investor Future Fund also participated in this round.

Amazon’s joint health-care venture finally has a name: Haven

The joint health-care venture between Amazon AMZN , J.P. Morgan JPM and Berkshire Hathaway BRK.A finally has a name: “Haven.”

Top 15 Best-Selling Drugs of 2018

For American patients aching for relief from the sky-high price of drugs, the news has been decidedly mixed recently.

Study: Memories of music cannot be lost to Alzheimer’s and dementia

The part of your brain responsible for ASMR catalogs music, and appears to be a stronghold against Alzheimer’s and dementia.

Houston scientist wins Nobel Prize for breakthrough cancer treatment – CultureMap Houston

The already much-heralded University of Texas MD Anderson Cancer Center has just scored global bragging rights. James Allison, Ph.D., a scientist at MD Anderson Cancer Center, has been awarded the 2018 Nobel Prize in Physiology or Medicine, it was announced on October 1.

Home | About BHI | BHI News | Programs | Partners | Contact

Copyright © BioHealth Innovation 2017
All Rights Reserved.

March 19, 2019

Love0

345th Edition – March 12, 2019

By adminBHI Weekly News Archives

BioHealth Innovation

If you are having trouble viewing this email, please click here

March 18, 2019

FOUNDING MEMBER OF

FOURTH ANNUAL CRAB TRAP COMPETITION – Final Week to Apply

YOU THOUGHT SHARK TANK WAS TOUGH?

Submit your application for a chance to be named the Startup with the Most Commercial Potential at the BioHealth Capital Region Forum, win $10,000 and more!

APPLICATION DEADLINE: March 15, 2019

FINALISTS ANNOUNCED: March 21, 2019

PRESENT AT THE BIOHEALTH CAPITAL REGION FORUM APRIL 9, 2019PRESENT AT THE BIOHEALTH CAPITAL REGION FORUM APRIL 9, 2019

Finalists will have a chance to win the grand prize by presenting in front of a panel of prominent industry funding experts and executives.

Distinguished Judges:

Moderator – Rich Bendis, President and CEO, BioHealth Innovation

2019 Judges

John Rubin, Executive Director, JP Morgan Private Bank
Charles J. Andres, Intellectual Property Associate, Wilson Sonsini Goodrich & Rosati (WSGR)
Raghav Bhargava, Associate, New Enterprise Associates (NEA)
Ethel Rubin, Entrepreneur in Residence, NIH
Shaun Grady, Vice-President Business Development Operations, AstraZeneca
Norm Marcus, MD, Venture Partner, Sanderling Ventures

PRIZES

Grand Prize provided by WSGR $10,000

Visibility in front of hundreds of attendees and prominent industry and venture capital judges

CRITERIA

Product, Technical Feasibility, Marketing/Strategy, Leadership Team, Financial/Projection

PAST WINNERS: Sonavex (2016) LifeSprout (2017) Galen Robotics (2018)

2019 BioHealth Capital Region Forum – Registration Open

April 8 + 9, 2019

One MedImmune Way, Gaithersburg, MD 20878

This invitation-only event is free for executive level biotech leaders and is presented by BioHealth Innovation, VirginiaBio, Maryland Tech Council, University System of Maryland, Children’s National Health Network, HemoShear, GSK, BeneVir, Quality Biological, Johns Hopkins University and AstraZeneca. Maryland, Virginia, and Washington, DC set the bar high for biotech innovation. So please join us for our Annual BioHealth Capital Region Forum that will highlight the accomplishments of today and chart our successes of tomorrow.

Register at bhcrf2019.eventbrite.com

For more information about our speakers and event schedule, please visit www.bhcrforum.com.

Behrman Capital Makes Significant Investment in Emmes

Emmes today announced that Behrman Capital, a leading private equity firm, has made a significant investment in the company. The capital will allow Emmes, one of the Washington area’s top 100 largest private companies, to expand and strengthen its service offerings and international presence.

Sonavex Receives FDA 510(k) Clearance for EchoSure

Sonavex, Inc., a privately held medical device company focused on empowered patient care, announced today that on March 8, 2019 it received 510(k) clearance from the U.S. Food and Drug Administration for its EchoSure device to deliver definitive blood flow data on demand.

Successful Marketing & PR Strategies for Your Startup (4/4)

PR and Marketing – What’s the difference?
How do you establish your brand?
Are their tips for marketing on a tight budget?
What should an effective marketing plan include?
How can a strong digital strategy build credibility?
How can I get press coverage for my product/service/technology?
What type of budget is realistic for marketing/public relations activities?

Learn the answers to these questions and more through the April 4th PathFinder Innovation Program. (There is no charge to attend in person or by videoconference, however, pre-registration by NOON, 4/2 is required).

8:15 a.m. Networking and Coffee8:30 a.m. – Issues Overview and Discussion (in person/by videoconference)

Pam Clark, Principal, Creative Director – Clark Concepts
Warren Ellis, VP of Marketing, Montgomery County Economic Development Corp.
Rachel Wojnilower, Digital Marketing Manager – Clark Concepts
Jennifer Owers, WebDesigner/Project Manager – Clark Concepts

9:45 a.m. – 1:1 Office Hours (in person/by videoconference)*

This program is cosponsored by BioHealth Innovation, Launch Workplaces, and TEDCO. It is open to anyone in the BioHealth Capital Region.

To register/for more information, email: BHI@BioHealthInnovation. (Please include in your RSVP: Your company name, your title and contact information, the type of product(s) services you are promoting, and your interest in a 1:1 meeting following the overview session.)

*Attendance at Overview in person/by videoconference is required to participate in 1:1 sessions.

BHI Entrepreneur-in-Residence Feedback Session – March 20th

Are you a start-up in Maryland, DC or Virginia seeking feedback on your biohealth business idea, pitch deck, or commercialization plan? Sign up by noon 3/19 to schedule your feedback session with BHI Entrepreneurs-in-Residence (who have industry experience in therapeutics, Dx, medtech and more) next Wednesday, March 20th. (The next session is scheduled for 3/20 and 5/22.) Pre-registration is required; sign up here(“EIR resource” at BHI). For questions/more information, contact BHI.

TEDCO Generates $1.6 Billion in Economic Benefits to the State of Maryland and Supports 7,746 Maryland Jobs, According to New Independent Study | TEDCO

The Maryland Technology Development Corporation (TEDCO), Maryland’s economic engine for technology companies, announced today the findings of an independent economic impact study detailing the economic development contributions of TEDCO’s five core programs to the state of Maryland.

Hopkins professors receive grants to commercialize research – Maryland Daily Record

Four Johns Hopkins professors received grants through a fund created to help faculty put their research on a path to commercialization.

The professors received grants between $25,000 and $100,000 from the Bisciotti Foundation Translational Fund.

UM BioPark Driving Growth in Maryland Economy – University of Maryland, Baltimore

UMB has long been one of the state’s most powerful economic drivers, stimulating $3 billion in economic activity in 2018, up from $2.8 billion in 2016. A significant factor in that growth is the UM BioPark, which occupies 14 acres in West Baltimore providing laboratory and office space to 41 biotechnology companies and over 1,000 employees.

Pediatric orthopedic & spine device accelerator program accepting pitches — 5 things to know

The National Capital Consortium for Pediatric Device Innovation is accepting applications for its Make Your Medical Device Pitch for Kids competition.

These 3 tech investors are the most active in the DMV: report – Technical.ly DC

Three investment firms topped the list of local tech investors in the DMV region according to CB Insights‘ report, The United States of Venture Capital.

Chinese-born legislator makes history in US local politics

One woman is making her mark at the highest level of U.S. local politics.

She was born in China and successfully carved her path all the way to the state capitol.

CGTN’s Frances Kuo has her story.

Counties Support Kirwan “Blueprint” Bill as Worthy First Steps – Conduit Street

On Wednesday, MACo Legislative Committee members Craig Rice (Montgomery), Jan Gardner (Frederick), and Laura Price (Talbot) joined Executive Director Michael Sanderson in support of SB 1030 The Blueprint for Maryland’s Future.

Navigating the Challenges of Cell-Based Immunotherapies

Cell therapy is emerging, cell by cell, into the repertoire of medical therapies. However, it still has not broken into mainstream use. For instance, there are only two FDA-approved chimeric antigen receptor (CAR) T-cell treatments in the United States: Kymirah, Novartis’s treatment for acute lymphoblastic leukemia, and Yescarta, Kite Pharma’s treatment for non-Hodgkin’s lymphoma.

Rare disease racers speak out, stand tall at Racefor7 events in the U.S. and India

Visibility, speaking out, courage and organization. Forty years ago, these were the things that brought the Orphan Drug Act to life. On Sunday, February 24, across the U.S. and India, over 7,000 supporters gathered in the same passion: speaking out and bringing visibility to the more than 7,000 disorders collectively known as rare diseases, organized under the banner of Racefor7USA and its parent organizations, the Organization for Rare Disease India (ORDI) and Organization for Rare Diseases India in the U.S. (ORDIUSA).

Be Bold. Cutting-edge Lab Space Available at the Gateway of the NIH. Delivering Summer 2021.

Cutting Edge Lab Space Available

The NIH is the cornerstone to the world scientific community and is the largest life sciences engine in the US.

Bethesda Bio gives life science companies the ability to be on the doorstep of this invaluable wealth of resources, community, talent, technology, intellectual property, clinical studies. The existing Bethesda central business district provides a vibrant live, work and play environment to recruit and retain the best scientific minds. Over the past two decades, Bethesda has been the center of Montgomery County and the hub of innovation.

London HIV patient becomes second worldwide in remission, giving hope – Business Insider

An HIV-positive man in Britain has become the second known adult worldwide to be cleared of the AIDS virus after he received a bone marrow transplant from an HIV resistant donor, his doctors said.

Home | About BHI | BHI News | Programs | Partners | Contact

Copyright © BioHealth Innovation 2017
All Rights Reserved.

March 18, 2019

Love0

344th Edition – March 5, 2019

By adminBHI Weekly News Archives

BioHealth Innovation

If you are having trouble viewing this email, please click here

March 18, 2019

FOUNDING MEMBER OF

FOURTH ANNUAL CRAB TRAP COMPETITION – Only 2 Weeks Left to Register

YOU THOUGHT SHARK TANK WAS TOUGH?

Submit your application for a chance to be named the Startup with the Most Commercial Potential at the BioHealth Capital Region Forum, win $10,000 and more!

APPLICATION DEADLINE: March 15, 2019

FINALISTS ANNOUNCED: March 21, 2019

PRESENT AT THE BIOHEALTH CAPITAL REGION FORUM APRIL 9, 2019PRESENT AT THE BIOHEALTH CAPITAL REGION FORUM APRIL 9, 2019

Finalists will have a chance to win the grand prize by presenting in front of a panel of prominent industry funding experts and executives.

Distinguished Judges:

Moderator – Rich Bendis, President and CEO, BioHealth Innovation

2019 Judges

John Rubin, Executive Director, JP Morgan Private Bank
Charles J. Andres, Intellectual Property Associate, Wilson Sonsini Goodrich & Rosati (WSGR)
Raghav Bhargava, Associate, New Enterprise Associates (NEA)
Ethel Rubin, Entrepreneur in Residence, NIH
Shaun Grady, Vice-President Business Development Operations, AstraZeneca
Norm Marcus, MD, Venture Partner, Sanderling Ventures

PRIZES

Grand Prize provided by WSGR $10,000

Visibility in front of hundreds of attendees and prominent industry and venture capital judges

CRITERIA

Product, Technical Feasibility, Marketing/Strategy, Leadership Team, Financial/Projection

2019 BioHealth Capital Region Forum – Registration Open

April 8 + 9, 2019

One MedImmune Way, Gaithersburg, MD 20878

This invitation-only event is free for executive level biotech leaders and is presented by BioHealth Innovation, VirginiaBio, Maryland Tech Council, University System of Maryland, Children’s National Health Network, HemoShear, GSK, BeneVir, Quality Biological, Johns Hopkins University and AstraZeneca. Maryland, Virginia, and Washington, DC set the bar high for biotech innovation. So please join us for our Annual BioHealth Capital Region Forum that will highlight the accomplishments of today and chart our successes of tomorrow.

Register at bhcrf2019.eventbrite.com

For more information about our speakers and event schedule, please visit www.bhcrforum.com.

Strong interest in Non-Dilutive Funding Programs

More than 120 people registered for last week’s SBIR Workshop at IBBR organized by BioHealth Innovation in partnership with Launch Workplaces and support from TEDCO and NIH FCU.

The event featured program overviews, “how to” sessions regarding specific aspects of proposal development and 1:1 partnering meetings with the program managers.

Speakers included: Todd Haim, Ph.D., Chief, Office of Small Business Research NIA; Mike Pieck, Ph.D., Small Business Coordinator, NHLBI; Maureen (Cusick) Thomas, Outreach Coordinator, NIA;Victor Prikhodko, Business Advisor, NIDA; Amir Rahbar, PhD, MBA, Program Director, NCI; Vladimir M. Popov, PhD, Business Dev. Manager, NCI-FNL;Amir Rahbar, PhD, MBA, Program Director, NCI; Henry Ahn, Program Director SBIR/STTR, NSF; and Colleen Gibney, SBIR Deputy Project Mgr, USAMRMC.

44% of the attendees had applied for SBIR funding before with half of these innovators receiving a Phase 1. Only 16% had received a Phase II award. The majority of attendees were from Montgomery and Frederick Counties and the City of Baltimore. However, registrants also traveled from Virginia, DC, Illinois and Pennsylvania.

BioHealth Innovation Entrepreneur-in-Residence Feedback – March 20th

Are you a start-up in Maryland, DC or Virginia seeking feedback on your biohealth business idea, pitch deck, or commercialization plan? Sign up by noon 3/19 to schedule your feedback session with BHI Entrepreneurs-in-Residence, who have industry experience in therapeutics, Dx, medtech and more March 20th. (Future session scheduled for 5/22.) Pre-registration is required; sign up here (“EIR resource” at BHI). For questions/more information, contact BHI.

MaxCyte Announces Multi-Drug Clinical & Commercial Agreement with Kite, a Gilead Company

MaxCyte, the global cell-based medicines and life sciences company, announced today that it has expanded its relationship with Kite, a Gilead Company, by entering into a multi-drug clinical and commercial agreement. Under the terms of the agreement, Kite will use MaxCyte’s Flow Electroporation® Technology to enable non-viral cell engineering for development of multiple CAR-T drug candidates for up to 10 targets.

NexImmune raising $10M for AML drug trials – Washington Business Journal

The company has already raised about $40 million to date.

State Department awards Emergent BioSolutions contract for chemical warfare countermeasures – Homeland Preparedness News

Emergent BioSolutions announced today that the company has signed a deal with the U.S. Department of State to establish a supply chain for certain medical countermeasures that address chemical warfare agents.

NCC-PDI Announces $250K Pediatric Pitch Competition for Orthopedic Medical Device Innovators

The National Capital Consortium for Pediatric Device Innovation (NCC-PDI) is now accepting applications for its “Make Your Medical Device Pitch for Kids!” competition. The competition is focused on pediatric devices developed for use in the orthopedic and spine sector, an area of critical need which lacks innovation. Winning companies receive awards up to $50,000 and are invited to participate in the newly created NCC-PDI “Pediatric Device Innovator Accelerator Program” led by MedTech Innovator.

Gilead’s Kite pens 10-target CAR-T tech deal with MaxCyte – FierceBiotech

Gilead’s Kite Pharma has expanded its CAR-T agreement with MaxCyte. The revised deal gives Kite the chance to apply MaxCyte’s transfection technology to up to 10 targets.

Rexahn Pharmaceuticals Appoints Lara S. Sullivan to its Board of Directors :: Rexahn Pharmaceuticals, Inc. (RNN)

Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, today announced the appointment of Lara S. Sullivan, M.D. to its board of directors.

Personal Genome Diagnostics Welcomes New Members to Board of Directors, Bringing Proven, Industry-Leading Experience in Precision Medicine and Healthcare Policy

Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, announced today that it has added two new members to its Board of Directors, Dr. Kavita Patel and Garry Allen Nicholson. Dr. Patel and Mr. Nicholson bring significant healthcare expertise that is aligned with and can further empower PGDx’s corporate growth strategy of driving global access to precision medicine in oncology.

Local Entrepreneur Brings Swedish Company AcouSort to BioHealth Capital Region · BioBuzz

For every AstraZeneca, there are hundreds of small biotech startups and scores of life science innovators that are critical to growing the BioHealth Capital Region. For every new biotech flush with investment cash, scores of smart, entrepreneur-scientists with great ideas and technology struggle to find regional funding partners.

BioFactura CEO Dr. Darryl Sampey Shares his Entrepreneurial Journey at Frederick’s StartupGrind Event – BioBuzz

Dr. Darryl Sampey has been through the grind as CEO of Frederick’s BioFactura, a thriving biotech company that’s a key part of the BioHealth Capital Region’s second largest biotech hub. On a rainy, cold February night at FITCI, Sampey shared BioFactura’s compelling story during a “fireside chat” hosted by StartUp Grind’s Frederick chapter.

BioBuzz with JHU MoCo – March 13th

When: Wednesday, March 13, 2019 from 5:00 PM to 7:00 PM

Where: Bar Louie 150 Gibbs St Rockville, MD 20850

Join BioBuzz and Founding Sponsor JHU MoCo for our next exciting event of 2019 at Bar Louie in Rockville on March 13th.

The Johns Hopkins University Krieger School of Arts and Sciences created the Center for Biotechnology Education to engage diverse audiences in the world of biotechnology and to prepare the leaders of today, tomorrow and the next generation for the challenges of the 21st century.

New ebook: How Protenus fast-tracked hiring with a more focused strategy – Technical.ly Baltimore

In late 2017, Baltimore-based healthcare startup Protenus was reverberating from a year of growth.

Her biotech firm solves medical mysteries. (And no, it’s not Theranos.)

I was dubious when Crystal Icenhour approached me to write about her medical testing company.

New study finds $9 billion in technology sales following NCI-funded research | TechLink

The National Cancer Institute’s investment in small business research grants has supported strong economic growth, including $9 billion in sales of new technologies.

Want to raise $75M in funding? NEA investor explains how Baltimore’s PGDx did it – Baltimore Business Journal

Justin Klein, as a former investor with NEA, helped lead PGDx’s $21.4 million Series A in 2015 and its $75 million Series B last year.

Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn’t Died – RealMoney

The biotech sector has been a strong performer in 2019 after becoming quite oversold during the plunge in the high-beta parts of the market in the fourth quarter of 2018. Helping the sector recover and get off to a raucous start to the New Year were large buyouts of Celgene Corp(CELG) and Loxo Oncology Inc(LOXO) to start 2019, both with significan…

NEA is raising its biggest fund ever – – again – TechCrunch

New Enterprise Associates, the 41-year-old venture firm with offices in Menlo Park; San Francisco; Boston; New York; Chevy Chase, Md.; and Washington, D.C., is raising its biggest fund ever, shows a new SEC filing that shows target of $3.6 billion.

Alexandria RE Equities Launches ‘GradLabs’ Product in San Diego | GlobeSt

Office REIT Alexandria Real Estate Equities reports it has launched a new product geared to providing post-seed-stage life science companies with turnkey, fully furnished office/laboratory suites.

A $100 Genome Within Reach, Illumina CEO Asks If World Is Ready

Francis deSouza Photographer: Jeff Spicer/PA Wire via AP For years, the cost to decode a full human genome has been falling much like computer processing costs — from hundreds of thousands of dollars per person to about $1,000 today. With a $100 genome getting closer, the CEO of the top maker of DNA sequencers thinks the world may not be ready.

RFI Deadline Approaching: Understanding the Health of Women and the Role of Sex/Gender in Mechanisms of Heart, Lung, Blood, and Sleep Diseases and Disorders

The biomedical research community has made major progress in achieving a balance of men and women in human studies, however compelling questions about the underlying mechanisms that increase women’s risk or resilience for certain heart, lung, blood, and sleep (HLBS) diseases continue to challenge the scientific and medical community.

In support of its Strategic Vision, the National Heart, Lung, and Blood Institute (NHLBI) is advancing a scientific research agenda for women’s health. As part of that agenda, the Institute has issued a Request for Information “Understanding the Health of Women and the Role of Sex/Gender in Mechanisms of Heart, Lung, Blood, and Sleep Diseases and Disorders.” The RFI offers the research community, health care professionals, patient advocates, and others an opportunity to provide input on topics ranging from scientific gap areas in mechanisms of HLBS diseases, to training and resource needs, among other topics.

The NHLBI greatly values your perspective as it works with the wider scientific community to uncover the mechanisms of disease that will set a stronger foundation for clinical research focused on more effective prevention and treatment strategies for HLBS diseases and disorders in women. Please submit your responses via email to WHWGRFI@nhlbi.nih.gov by March 15, 2019. Don’t forget to include the Notice number (NOT-HL-18-660) in the subject line.

2018 was a record year for venture capital, but not for women founders – Washington Business Journal

The share of funding going to women-founded startups went down despite a massive influx of dollars to the region.

Pfizer: Countries free-riding on US innovation – BBC News

Albert Bourla told a US Senate hearing that other nations are “free-riding on American innovation”.

Sanofi, Bayer and Roche execs underscore the value of digital therapeutics – MedCity News

Biopharma companies have long been looking for a way to go beyond the molecule/pill.The nascent but growing digital therapeutics industry set to grow to $10 billion by 2023 may be guiding that way forward, according to a panel discussion on the second day of the DTx (Digital Therapeutics) West conference in San Mateo, California.

Van Hollen: Despite Trump, NIH Significantly ‘Better Off’ In Terms of Funding

Funding for the Bethesda-based National Institutes of Health is up by 14 percent during the two years that President Donald Trump has been in the White House — but it’s despite and not because of the president, according to Maryland Sen. Chris Van Hollen.

New Blood Test for 8 Common Cancers – Johns Hopkins Medicine

Johns Hopkins researchers have developed a unique, noninvasive blood test that detects proteins and gene mutations from eight common cancers. The test, called CancerSEEK, screens for cancers that account for more than 60 percent of U.S. cancer deaths.

This Viral Therapy Could Help Us Survive the Superbug Era

In November 2015, infectious disease epidemiologist Steffanie Strathdee and her husband, evolutionary psychologist Tom Patterson, were spending the week of Thanksgiving exploring pyramids and pharaoh’s tombs in Egypt when Patterson came down with what seemed like a nasty bout of food poisoning aboard their cruise ship. But as his condition rapidly deteriorated and he had to be emergency medevac’d, first to Germany and then to the medical center at UC San Diego, where both scientists were on staff, blood and imaging tests revealed why Patterson’s body was failing. A soccer-ball-sized cyst in his abdomen was infected—teeming with one of the most dangerous, antibiotic-resistant bacteria in the world.

Home | About BHI | BHI News | Programs | Partners | Contact

Copyright © BioHealth Innovation 2017
All Rights Reserved.

March 18, 2019

Love0

343rd Edition – February 26, 2019

By adminBHI Weekly News Archives

BioHealth Innovation

If you are having trouble viewing this email, please click here

February 26, 2019

FOUNDING MEMBER OF

2/28 SBIR & Non-Dilutive Funding Workshop

University of Maryland Institute for Bioscience & Biotechnology Research, 9600 Gudelsky Drive, Rockville, MD 20850

Register NOW: https://tinyurl.com/BHISBIR2019

8:00 a.m. – Networking and Registration
8:30 a.m. – Welcome
8:35 a.m. – SBIR Funding Opportunities at the National Institutes of Health
- National Heart, Lung, and Blood Institute
- National Institute on Aging
- National Institute on Drug Abuse
- National Cancer Institute
9:45 a.m. – Partnership Opportunities with NCI Frederick National Lab
10:00 a.m. – BREAK
10:20 a.m. – SBIR Funding Opportunities with the National Science Foundation
11:00 a.m. – BREAK
11:15 a.m. – SBIR Funding Opportunities with USAMRC
11:45 a.m. – Lunch
12:45 p.m. – (1:1 Room Set)
1:00 p.m. – Writing Your Specific Aims Page OR 1:1 Meetings* (available simultaneously)
1:30 p.m. – Writing Your Phase II Commercialization Plan OR 1:1 Meetings* (available simultaneously)
2:00 p.m. – Writing Your Specific Aims Page OR 1:1 Meetings* (available simultaneously)
2:30 p.m. – Writing Your Phase II Commercialization Plan OR 1:1 Meetings* (available simultaneously))
3:00 p.m. – 1:1 Meetings* (NIH only)
4:00 p.m. – Adjourn

Pre-Registration REQUIRED: RSVP by noon, February 26 at https://tinyurl.com/BHISBIR2019No charge for entrepreneurs to attend • NOTE: Most 1:1 meeting(s) timeslots now are booked but when you list your agency interests in the RSVP we will be certain to let them know to follow up with you with more information.

FOURTH ANNUAL CRAB TRAP COMPETITION

YOU THOUGHT SHARK TANK WAS TOUGH?

NOW ACCEPTING APPLICATIONS at

https://form.jotform.com/90276838255163

Submit your application for a chance to be named the Startup with the Most Commercial Potential at the BioHealth Capital Region Forum, win $10,000 and more!

APPLICATION DEADLINE: March 8, 2019

FINALISTS ANNOUNCED: March 21, 2019

PRESENT AT THE BIOHEALTH CAPITAL REGION FORUM APRIL 9, 2019PRESENT AT THE BIOHEALTH CAPITAL REGION FORUM APRIL 9, 2019

Finalists will have a chance to win the grand prize by presenting in front of a panel of prominent industry funding experts and executives.

Distinguished Judges:

Moderator – Rich Bendis, President and CEO, BioHealth Innovation

2019 Judges

John Rubin, Executive Director, JP Morgan Private Bank
Charles J. Andres, Intellectual Property Associate, Wilson Sonsini Goodrich & Rosati (WSGR)
Raghav Bhargava, Associate, New Enterprise Associates (NEA)
Ethel Rubin, NIH Entrepreneur in Residence
Shaun Grady, Vice-President Business Development Operations, AstraZeneca

PRIZES

Grand Prize provided by WSGR $10,000

Visibility in front of hundreds of attendees and prominent industry and venture capital judges

CRITERIA

Product, Technical Feasibility, Marketing/Strategy, Leadership Team, Financial/Projection

SAVE THE DATE – 2019 BioHealth Capital Region Forum

April 8 + 9, 2019

One MedImmune Way, Gaithersburg, MD 20878

This invitation-only event is free for executive level biotech leaders and is presented by BioHealth Innovation, VirginiaBio, Maryland Tech Council, University System of Maryland, Children’s National Health Network, HemoShear, GSK, BeneVir, Quality Biological, Johns Hopkins University and AstraZeneca. Maryland, Virginia, and Washington, DC set the bar high for biotech innovation. So please join us for our Annual BioHealth Capital Region Forum that will highlight the accomplishments of today and chart our successes of tomorrow.

Register at bhcrf2019.eventbrite.com

For more information about our speakers and event schedule, please visit www.bhcrforum.com.

Danaher acquires GE Biopharma for $21.4B – Washington Business Journal

The deal is expected to close in the fourth quarter of this year.

BioHealth Innovation Entrepreneur-in-Residence Feedback – Feb. 27th

Are you a start-up in Maryland, DC or Virginia seeking feedback on your biohealth business idea, pitch deck, or commercialization plan? Sign up by noon 3/26 to schedule your feedback session with BHI Entrepreneurs-in-Residence, who have industry experience in therapeutics, Dx, medtech and more, next Wednesday, February 27th. (Future sessions scheduled for 3/20 and 5/22.) Pre-registration is required; sign up here (“EIR resource” at BHI). For questions/more information, contact BHI.

EXCLUSIVE: Amazon Real Estate Head Holly Sullivan Has No Regrets About The HQ2 Search

Amazon changed the rules of economic development when it announced a 50,000-job HQ2 sweepstakes in 2017. While most searches for large facilities happen behind closed doors, the Seattle tech giant kicked off an unprecedented, high-stakes, public battle for its next corporate home.

Maryland still outpacing California among best science, tech environments – Baltimore Business Journal

Maryland has the most computer and data scientists in the U.S., and the second-highest concentrations of engineers and life scientists.

RoosterBio Announces Plans to Expand Facility in Frederick, MD

RoosterBio, Inc, a privately held regenerative medicine manufacturing platform technology company announced plans today to expand the company’s footprint in Frederick, MD after a year of rapid growth.

Qiagen Gets Access to the Largest Genetic Database on Antibiotic Resistance

Under a new licensing deal, Qiagen will gain access to a big genetics database from Vienna-based Ares Genetics, which could help tackle the global health crisis of antibiotic resistance.

Microsoft, global health organizations launch 3 tech programs to catch rare diseases in children

Microsoft outlined how emerging technologies can support diagnosis of rare diseases among children in a report released Feb. 20.

Rare diseases affect almost 350 million people globally, and they can take an average of five years to diagnose, according to the report.

Antidote Therapeutics teams up with National Cancer Institute, seeks funding for nicotine-blocking drug candidate – Washington Business Journal

Matt Kalnik wants to make smoking less addictive.

His clinical-stage company, Gaithersburg-based Antidote Therapeutics Inc., is developing a drug that would diminish the effects of nicotine in the body — to both treat diseases worsened by nicotine and help smokers quit. The businesses is looking to raise between $5 million and $10 million to run over the next two years and get its lead candidate to clinical trials.

Maryland Momentum Fund accepting applications | Office of Technology Commercialization

The Maryland Momentum Fund is a newly-created mechanism for investing in promising early stage companies associated with the University System of Maryland (USM). Maryland-based companies that are seeking equity financing or debt financing that is convertible into equity may apply. The funding provided by the Fund will normally be in the range of $150K-$250K, with a ceiling of $500K. Recipients of this funding must obtain a matching investment (1:1) within six months, in either direction, from the date of commitment by the Fund.

TEDCO Creates Task Force to Support Women Entrepreneurs in Maryland

The Maryland Technology Development Corporation (TEDCO) announced today the formation of the Task Force for Women Entrepreneurs. The task force will be dedicated to the recruitment, funding, and operational support of women-owned and-led startups in Maryland.

University of Maryland Greenebaum Comprehensive Cancer Center Now Among Select Institutions Certified to Administer CAR T-cell Therapy for Lymphoma | UM Greenebaum Comprehensive Cancer Center

The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) is now certified to offer a groundbreaking treatment for non-Hodgkin lymphoma, in which a patient’s own immune cells are genetically engineered to recognize and attack the cancer.

Top 10 Immuno-Oncology Startups – GEN – Genetic Engineering and Biotechnology News

GlaxoSmithKline (GSK)’s recently announced $4.2 billion partnership to co-develop and co-commercialize Merck KGaA, Darmstadt’s cancer immunotherapy candidate M7824 was a reminder of just how much biopharma giants are willing to invest in a therapeutic area that has generated sometimes-dazzling results.

Kauffman Indicators of Entrepreneurship

The Kauffman Indicators of Entrepreneurship offers in-depth measures, reports, and accompanying interactive data visualizations that present entrepreneurial trends in the United States.

Like the rest of biopharma investors, corporate VCs love oncology | Evaluate

Novartis scatters its VC seeds widely by leading rounds across a variety of therapy areas, although oncology still represents a big share of its funding activity.

If We Don’t Develop Best Practices Ourselves, the Government Will

To spare you all a power point presentation, I thought I’d share some thoughts today about how and why our tech transfer system was created and the importance of practitioners continually developing best practices to maintain it.

Woody Allen said that half of life is showing up. Perhaps the other half is working with people who give you the opportunity to show what you can do.

MPM Capital raises $400M in seventh venture fund – MedCity News

A life sciences-focused venture capital firm based near Boston has raised more than one-third of a billion dollars to invest in early-stage companies.

Why Food Could Be the Best Medicine of All – Time

When Tom Shicowich’s toe started feeling numb in 2010, he brushed it off as a temporary ache. At the time, he didn’t have health insurance, so he put off going to the doctor. The toe became infected, and he got so sick that he stayed in bed for two days with what he assumed was the flu. When he finally saw a doctor, the physician immediately sent Shicowich to the emergency room. Several days later, surgeons amputated his toe, and he ended up spending a month in the hospital to recover.

Home | About BHI | BHI News | Programs | Partners | Contact

Copyright © BioHealth Innovation 2017
All Rights Reserved.

February 28, 2019

Love0

342nd Edition – February 20, 2019

By adminBHI Weekly News Archives

BioHealth Innovation

If you are having trouble viewing this email, please click here

February 20, 2019

FOUNDING MEMBER OF

Charles J. Andres, Associate, Intellectual Property with Wilson Sonsini, Goodrich & Rosati (WSGR), joins Rich Bendis for BioTalk to discuss his career, the opportunities/challenges in this industry, and WSGR’s role in the BioHealth Capital

Charles Andres, Ph.D., RAC, is an associate in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati. He focuses on patent prosecution, strategic patent counseling, IP due diligence, drug and medical device FDA regulatory counseling, invalidity and non-infringement opinions, life-cycle management, Supreme Court and Federal Circuit amicus briefs, and related business matters.Charles Andres, Ph.D., RAC, is an associate in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati. He focuses on patent prosecution, strategic patent counseling, IP due diligence, drug and medical device FDA regulatory counseling, invalidity and non-infringement opinions, life-cycle management, Supreme Court and Federal Circuit amicus briefs, and related business matters.

Charlie has significant experience drafting patent applications, prosecuting patent applications in the U.S. and abroad, and evaluating the claims of issued patents. He has won cases before the Board of Patent Appeals and Interferences by brief and on oral argument. Patents Charlie has obtained have been listed in the Orange Book and asserted against a generic pharmaceutical manufacturer, and he has drafted and filed multiple applications for patent term extension. Companies he has obtained patents for have been sold for a cumulative total of approximately $4 billion.

Listen now on iTunes , Google Play , and TuneIn.

FOURTH ANNUAL CRAB TRAP COMPETITION

NOW ACCEPTING APPLICATIONS at

https://form.jotform.com/90276838255163

Submit your application by March 1st for a chance to be named

‘the company with the most commercial potential’

at the BioHealth Capital Region Forum

Deadline for entries is March 1, 2019

Finalists will be announced March 21, 2019

Present at BioHealth Capital Region Forum April 9, 2019.

Finalists will have a chance to win the grand prize by presenting in front of a panel of world-class judges.

PRIZES

Grand Prize provided by WSGR $10,000

Visibility in front of hundreds of industry leaders and prominent industry funding experts and executives.

CRITERIA

Product, Technical Feasibility, Marketing/Strategy, Leadership Team, Financial/Projection

SAVE THE DATE – 2019 BioHealth Capital Region Forum

April 8 + 9, 2019

One MedImmune Way, Gaithersburg, MD 20878

This invitation-only event is free for executive level biotech leaders and is presented by BioHealth Innovation, VirginiaBio, Maryland Tech Council, University System of Maryland, Children’s National Health Network, HemoShear, GSK, BeneVir, Quality Biological, Johns Hopkins University and AstraZeneca. Maryland, Virginia, and Washington, DC set the bar high for biotech innovation. So please join us for our Annual BioHealth Capital Region Forum that will highlight the accomplishments of today and chart our successes of tomorrow.

Register at bhcrf2019.eventbrite.com

For more information about our speakers and event schedule, please visit www.bhcrforum.com.

AstraZeneca retires MedImmune brand – Washington Business Journal

But not everything is expected to change at the Gaithersburg campus.

AURP’s Brian Darmody looks to make College Park office a hub for research parks – Technical.ly Baltimore

Among the organizations taking glass-enclosed office space in the recently opened WeWork at University of Maryland College Park is an organization looking to promote research parks that cluster minds in science and business.

Are the big corporate venture arms retreating? – Evaluate

At the beginning of this decade, when the fallout of the financial crash was still being felt and traditional venture firms were struggling to raise money, the investment arms of big pharma companies stepped in to fill a funding gap that was starving start-ups. Fast forward to the current period of plenty and, while corporate cash is no longer quite so crucial to the ecosystem, many of these units remain enthusiastic backers of early-stage science.

American Gene Technologies Signs Research Agreement with NIAID for Experimental HIV/AIDS Cure Strategy | American Gene Technology

American Gene Technologies (AGT) recently signed a Research Collaboration Agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, for research studies on AGT’s cell and gene therapy for HIV/AIDS. AGT uses its proprietary, genetically modified, autologous cell product (AGT103-T) to reconstitute the immune response against HIV with the goal of reducing persistent viral reservoirs and achieving sustained virologic remission in infected individuals in the absence of antiretroviral therapy. Under this collaboration agreement, NIAID researchers will study the mechanism of action for AGT103-T to define its potential impacts on HIV disease.

BioHealth Innovation Entrepreneur-in-Residence Feedback – Feb. 27th

Are you a start-up in Maryland, DC or Virginia seeking feedback on your biohealth business idea, pitch deck, or commercialization plan? Sign up now to schedule your feedback session with BHI Entrepreneurs in Residence next Wednesday, February 27th. (Future sessions scheduled for 3/20 and 5/22.) Pre-registration is required; sign up here (“EIR resource” at BHI). For questions/more information, contact BHI.

2-28 SBIR & Non-Dilutive Funding Workshop Agenda Set!

University of Maryland Institute for Bioscience & Biotechnology Research, 9600 Gudelsky Drive, Rockville, MD 20850

Register NOW: https://tinyurl.com/BHISBIR2019

8:00 a.m. – Networking and Registration
8:30 a.m. – Welcome
8:35 a.m. – SBIR Funding Opportunities at the National Institutes of Health
- National Heart, Lung, and Blood Institute
- National Institute on Aging
- National Institute on Drug Abuse
- National Cancer Institute
9:45 a.m. – Partnership Opportunities with NCI Frederick National Lab
10:00 a.m. – BREAK
10:20 a.m. – SBIR Funding Opportunities with the National Science Foundation
11:00 a.m. – BREAK
11:15 a.m. – SBIR Funding Opportunities with USAMRC
11:45 a.m. – Lunch
12:45 p.m. – (1:1 Room Set)
1:00 p.m. – Writing Your Specific Aims Page OR 1:1 Meetings* (available simultaneously)
1:30 p.m. – Writing Your Phase II Commercialization Plan OR 1:1 Meetings* (available simultaneously)
2:00 p.m. – Writing Your Specific Aims Page OR 1:1 Meetings* (available simultaneously)
2:30 p.m. – Writing Your Phase II Commercialization Plan OR 1:1 Meetings* (available simultaneously))
3:00 p.m. – 1:1 Meetings* (NIH only)
4:00 p.m. – Adjourn

Pre-Registration REQUIRED: RSVP by noon, February 26 at https://tinyurl.com/BHISBIR2019No charge for entrepreneurs to attend • If seeking 1:1 meeting(s) please include organization(s) in RSVP.

Johns Hopkins Team to Commercialize Barrett’s Esophagus Epigenetic Biomarker Panel | GenomeWeb

A team of researchers led by the Johns Hopkins University of Medicine has developed a methylated epigenetic biomarker panel integrating a sponge-based collection tool and a methylated-bead PCR method that it believes can detect Barrett’s esophagus (BE).

Emergent BioSolutions (EBS) Appoints Seamus Mulligan to Board

Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of Seamus Mulligan to the company’s Board of Directors effective March 19, 2019. Mr. Mulligan was a co-founder and principal investor of Adapt Pharma Ltd. and served as its chairman and CEO from 2014 until 2018, when Adapt was acquired by Emergent.

A $3.6 million grant will help UMD researchers advance cancer research – Arc Publishing

The National Institute of Health awarded a University of Maryland research center team of scientists $3.6 million to help fund their work on the cells responsible for destroying cancer cells.

QIAGEN partners with Ares Genetics to advance global fight against antibiotic-resistant pathogens – MarketWatch

QIAGEN N.V. today announced a broad agreement with Ares Genetics, a subsidiary of Curetis N.V. CURE, -0.10% to develop innovative bioinformatics and assay solutions to accelerate research targeting the growing global health challenges posed by antibiotic-resistant bacteria.

Frederick-based Akonni Biosystems Awarded $3M NIH Phase 2 Award to Develop Low-Cost Tuberculosis Test

Akonni Biosystems, a molecular diagnostics (MDx) company that develops, manufactures, and intends to market advanced MDx systems, today announced receipt of a $3 million, three-year Phase II Small Business Innovation Research (SBIR) contract from the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). Akonni received the Phase I contract in August 2016.

Kousouris, Bailey Take New Leadership Roles at JHTV – JHTV

Steve Kousouris, who has been serving as Interim Executive Director of Technology Transfer at Johns Hopkins Technology Ventures since June, has assumed this role permanently effective Jan.1. Additionally, Mark Bailey, previously Associate Director of Finance, will assume responsibility for the portfolio that Steve has overseen since 2013 in the capacity of Director, Finance & Administration.

Kelly M. Schulz, State Secretary of Commerce – I95 Business

Kelly M. Schulz, the newly appointed state secretary of commerce, could be called the secretary of opportunity. Her vision for the state of Maryland is for economic development, job growth, full employment and economic prosperity for all families around the state.

Is that a robot? Dr. Bear Bot helps care for kids at local hospital. – The Washington Post

“How did you get in the robot?” That was the question a young patient at Children’s National Health System had on Thursday for Dr. Bear Bot.

18 charts to illustrate US VC in 2018 – PitchBook

Over the past couple of years, the term “record-breaking” has frequently been used to describe the state of venture capital in the US, as the space hits new heights with deal value, mega-rounds and fundraising. In 2018, some of these records reached heights not seen since the dot-com boom.

Pioneering Physician-Scientist to Receive 2019 Szent-Györgyi Prize for Progress in Cancer Research

The National Foundation for Cancer Research (NFCR) announced today that Steven A. Rosenberg, M.D., Ph.D., of the U.S. National Cancer Institute (NCI) has been selected to receive the 2019 Szent-Györgyi Prize for Progress in Cancer Research. The Prize selection committee awarded Dr. Rosenberg for not only revolutionizing—if not originating—the field now known as cancer immunotherapy but also remaining at its forefront. Chief of the NCI Center for Cancer Research’s surgery branch in Bethesda since 1974, his basic, translational and applied research efforts have contributed immeasurably to groundbreaking advances in therapy and the later development of drugs such as Chiron’s (later Novartis and Prometheus Labs’) Proleukin, Bristol-Myers Squibb’s Yervoy and Gilead’s Yescarta.

Unlucky 13: Top Clinical Trial Failures of 2018

Nuventra Pharma Sciences, a clinical pharmacology and PK/PD consultancy in Durham, NC, recently offered some insights on why clinical trials fail. In addition to biological considerations—such as pharmacokinetics, pharmacodynamic, and human response to a drug varying from animal models—Nuventra presented a list of reasons that included:

7 takeaways from HIMSS 2019 – MedCity News

Friday is the official last day of #HIMSS19 in Orlando. The annual healthcare conference, which began on Monday, February 11, was packed full of presentations, panels, products and people.

Novak Biddle from Roger Novak, Jack Biddle officially closes up shop – Washington Business Journal

The 22-year-old firm has invested in a number of well-known local companies.

Home | About BHI | BHI News | Programs | Partners | Contact

Copyright © BioHealth Innovation 2017
All Rights Reserved.

February 28, 2019

Love0

341st Edition – February 12, 2019

By adminBHI Weekly News Archives

BioHealth Innovation

If you are having trouble viewing this email, please click here

February 12, 2019

FOUNDING MEMBER OF

FOURTH ANNUAL CRAB TRAP COMPETITION

NOW ACCEPTING APPLICATIONS at

https://form.jotform.com/90276838255163

Submit your application by March 1st for a chance to be named

‘the company with the most commercial potential’

at the BioHealth Capital Region Forum

Deadline for entries is March 1, 2019

Finalists will be announced March 21, 2019

Present at BioHealth Capital Region Forum April 9, 2019.

Finalists will have a chance to win the grand prize by presenting in front of a panel of world-class judges.

PRIZES

Grand Prize provided by WSGR $10,000

Visibility in front of hundreds of industry leaders and prominent industry funding experts and executives.

CRITERIA

Product, Technical Feasibility, Marketing/Strategy, Leadership Team, Financial/Projection

Startup CXO Database

Are you an experienced biohealth entrepreneur seeking new opportunities in the BioHealth Capital Region? BioHealth Innovation is developing a database of experienced industry personnel willing to work in potential C-suite positions with our university and startup partners. If you would like to have your contact information and vita included in this database for their review, please email BHI an updated vita by this Thursday, February 14th.

Brian Darmody Announced as AURP CEO & Launches ‘AURP HQ2’ in Washington, DC Area

The Association of University Research Parks (AURP), a professional association of university-related research and science parks, announced the appointment of Brian Darmody, Associate Vice President of Corporate Engagement at the University of Maryland (UMD), as its new Chief Executive Officer (CEO). Additionally, the association has opened a new office at the UMD Discovery District in the Washington, DC area, to be known as ‘AURP HQ2.’ Mr. Darmody will immediately assume his new role as CEO at the new location. He will continue his role at UMD and plans to transition out of UMD over time.

BioHealth Innovation Entrepreneur-in-Residence Feedback – Feb. 27th

Are you a start-up in Maryland, DC or Virginia seeking feedback on your biohealth business idea, pitch deck, or commercialization plan. Sign up now to schedule your feedback session with BHI EIRs on Wednesday, February 27th. (Next sessions scheduled for 3/20 and 5/22.) Pre-registration is required; sign up here (“EIR resource”at BHI). For questions/more information, contact BHI.

2-28 SBIR & Non-Dilutive Funding Workshop Agenda Set!

University of Maryland Institute for Bioscience & Biotechnology Research, 9600 Gudelsky Drive, Rockville, MD 20850

Register NOW: https://tinyurl.com/BHISBIR2019

8:00 a.m. – Networking and Registration
8:30 a.m. – Welcome
8:35 a.m. – SBIR Funding Opportunities at the National Institutes of Health
- National Heart, Lung, and Blood Institute
- National Institute on Aging
- National Institute on Drug Abuse
- National Cancer Institute
9:45 a.m. – Partnership Opportunities with NCI Frederick National Lab
10:00 a.m. – BREAK
10:20 a.m. – SBIR Funding Opportunities with the National Science Foundation
11:00 a.m. – BREAK
11:15 a.m. – SBIR Funding Opportunities with USAMRC
11:45 a.m. – Lunch
12:45 p.m. – (1:1 Room Set)
1:00 p.m. – Writing Your Specific Aims Page OR 1:1 Meetings* (available simultaneously)
1:30 p.m. – Writing Your Phase II Commercialization Plan OR 1:1 Meetings* (available simultaneously)
2:00 p.m. – Writing Your Specific Aims Page OR 1:1 Meetings* (available simultaneously)
2:30 p.m. – Writing Your Phase II Commercialization Plan OR 1:1 Meetings* (available simultaneously))
3:00 p.m. – 1:1 Meetings* (NIH only)
4:00 p.m. – Adjourn

Pre-Registration REQUIRED: RSVP by noon, February 26 at https://tinyurl.com/BHISBIR2019No charge for entrepreneurs to attend • If seeking 1:1 meeting(s) please include organization(s) in RSVP.

MacroGenics’ stock price more than doubles on successful breast cancer study – MedCity News

Shares of MacroGenics went stratospheric Wednesday following the release of data from a pivotal Phase III study of the company’s lead drug candidate in breast cancer that beat many investors’ expectations.

VLP Therapeutics to Initiate First Clinical Trial of VLPM01 Malaria Vaccine

VLP Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for a clinical trial of the Company’s VLPM01 malaria vaccine. The Phase I/IIa clinical trial will begin recruiting participants in February 2019, and is designed to assess the safety, immunogenicity and efficacy of the VLPM01 vaccine. The clinical trial will be conducted at the Walter Reed Army Institute of Research (WRAIR) in Silver Spring, MD.

US FDA grants Breakthrough Therapy Designation for potential next-generation RSV medicine MEDI8897

AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for MEDI8897, an extended half-life respiratory syncytial virus (RSV) F monoclonal antibody (mAb) being developed for the prevention of lower respiratory tract infection (LRTI) caused by RSV.

The United States Of Venture Capital: The Most Active VC In Each State

Although startups based in California, New York, and Massachusetts have traditionally accounted for the majority of VC tech investment in the US, VCs are spurring other hotbeds of innovation across the country.

New Lab Space Designed to Attract Biotech Talent and Community Opens at 704 Quince Orchard – BioBuzz

When construction is completed this month, 704 QO will offer ready-to-occupy lab/office spaces for companies of all sizes. What really makes this new building stand out isn’t just the fully customizable individual lab units, but the suite of amenities that are tailored to the specific needs of emerging life science companies in the BioHealth Capital Region and the employees that work for them.

Look back at 10 of Baltimore tech’s biggest moments of the last decade – Technical.ly Baltimore

Today we’re celebrating around the Technical.ly Slack channel. It’s the 10th anniversary of Technical.ly’s founding in Philadelphia, marking a decade of local tech news and innovation community coverage.

PitchMasters™ hosts four emerging startups at January event, expands to Baltimore and New York – Shulman Rogers

PitchMasters™, a workshop-style event for entrepreneurs preparing for their first institutional capital raise, held its 2019 Kick Off and Alumni Event on Jan. 30, 2019. Four emerging startup companies, Skipiit, Trove Therapeutics, Uplift and VERALOX Therapeutics, practiced their pitching skills and gained insights from experienced entrepreneurs, investors, industry influencers and fellow PitchMasters™ alumni.

Growth In Life Sciences Innovation Triggers Demand For Real Estate Clusters

The life sciences industry is taking off, with the medical technology and biotech sectors expected to grow further as traditional pharmaceutical companies are joined by startups and incubator labs driving new research and development. And with life sciences innovation rising, so is demand for the space in which to innovate.

Beyond Wellness For the Healthy: Digital Health Consumer Adoption 2018 – Rock Health

Utilization of digital health services and technologies has been on the rise since we first began surveying the US adult population in 2015. Budding choices of wearables, apps, telemedicine, and other tech-enabled services make it easy for consumers to test out what it might be like to “go digital” for their health. In the first three years, our annual survey showed that tools for fitness and wellness represented a common (and low-risk) entry point for consumers to experiment with products that fit neatly into their already tech-enabled lifestyles. In the 2018 data that we examined for this report, we saw something different.

Home | About BHI | BHI News | Programs | Partners | Contact

Copyright © BioHealth Innovation 2017
All Rights Reserved.

February 28, 2019

Love0

340th Edition – February 5, 2019

By adminBHI Weekly News Archives

BioHealth Innovation

If you are having trouble viewing this email, please click here

February 5, 2019

FOUNDING MEMBER OF

FOURTH ANNUAL CRAB TRAP COMPETITION

NOW ACCEPTING APPLICATIONS at

https://form.jotform.com/90276838255163

Submit your application for a chance to be named

‘the company with the most commercial potential’

at the BioHealth Capital Region Forum.

Deadline for entries is March 1, 2019

Finalists will be announced March 21, 2019

Present at BioHealth Capital Region Forum April 9, 2019.

Finalists will have a chance to win the grand prize by presenting in front of a panel of prominent industry funding experts and executives.

Moderator – Rich Bendis, President and CEO, BioHealth Innovation
2019 Judges to be announced

PRIZES

Grand Prize provided by WSGR $10,000
Visibility in front of hundreds of attendees and prominent industry and venture capital judges

CRITERIA

Product
Technical Feasibility
Marketing/Strategy
Leadership Team
Financial/Projection

Dr. Julia Finkel, Pediatric Anesthesiologist, Children’s National Medical Center, joins Biotalk host Rich Bendis

Dr. Julia Finkel, Pediatric Anesthesiologist, Children’s National Medical Center, joins Biotalk host Rich Bendis to discuss pain care management, the founding of startup AlgometRx, and the funding of this new companyDr. Julia Finkel, Pediatric Anesthesiologist, Children’s National Medical Center, joins Biotalk host Rich Bendis to discuss pain care management, the founding of startup AlgometRx, and the funding of this new company.

Julia Finkel, M.D., is a pediatric anesthesiologist and director Pain Medicine Research and Development in the Sheikh Zayed Institute for Pediatric Surgical Innovation.

Dr. Finkel has extensive experience designing and conducting clinical trials relating to analgesics in children and has received both industry and federal funding of her research. Dr. Finkel is regularly invited to speak at national meetings on topics related to pediatric pain management.

Listen now on iTunes , Google Play , and TuneIn.

SBIR & Non-Dilutive Funding Workshop – February 28th

UMD IBBR – 9600 Gudelsky Drive, Rockville, MD 20850

February 28, 2019

Unique opportunity to meet 1:1 with multiple SBIR program managers and experts.

SCHEDULE

8:00 a.m. – 8:30 a.m. – Networking and Registration
8:30 a.m. – 12:00 p.m. – Program Overviews. Agencies represented:
- NSF (National Science Foundation)
- NIH NIA (National Institute on Aging)
- NIH NCI (National Cancer Institute)
- NIH NHLBI (National Heart, Lung, and Blood Institute)
- NIH NIDA (National Institute on Drug Abuse)
- US Army (invited)
12:00 p.m. – 1:00 p.m. – Networking Lunch
1:00 p.m. – 1:30 p.m. – Writing Specific Aims Page
1:30 – 2 p.m. – Writing Your Phase II Commercialization Program
2:00 – 2:30 p.m. – Q&A with All speakers
2:30 – 4:00 p.m. – 1:1 – Meetings with Program Managers*

Pre-Registration REQUIRED: RSVP by noon, February 26 at https://tinyurl.com/BHISBIR2019

No charge for entrepreneurs to attend • If seeking 1:1 meeting(s) please include organization(s) in RSVP.

*You do not have to participate in 1:1 meetings. However, to do so, you must attend the overview session in person.

Scoop: GSK’s venture team at SR One in talks to spin off from its big pharma founder, now under new R&D management – Endpoints News

The partners at SR One, a storied corporate biotech VC with investments across a wide range of drug developers on both sides of the Atlantic, are engaged in talks to split away from the pharma giant GlaxoSmithKline, according to sources familiar with a move that’s been in the works since at least late last year.

Cerecor Announces U.S. Headquarters Move Into Pharmaceutical Corridor of Rockville, Maryland

Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments in rare and orphan diseases in pediatrics and neurology, announced today that it has moved its U.S. Corporate Offices to 540 Gaither Road Suite 400 located in Rockville, Maryland. The company had previously been based in Baltimore, Maryland.

Montgomery County Economic Development Corporation Renews Support Commitment to Maryland Tech Council’s Venture Mentoring Services Program

Maryland Tech Council (MTC) announced today that the Montgomery County Economic Development Corporation (MCEDC) will continue its partnership with and support of MTC’s Venture Mentoring Services (VMS) program. MCEDC has funded the mentoring program for three years and will continue to support it in 2019-to further augment the growth of Montgomery County’s target industries-technology and life sciences, while providing a key component to sustain economic growth in the County.

GetWellNetwork poised to increase global footprint and drive digital health innovation across care continuum in 2019 | GetWellNetwork

GetWellNetwork, the Precision Engagement health care company reaching 10 million patients annually, announced today a pivotal 2018 which will propel the company into 2019 as it continues to lead the evolution of patient engagement. The company furthered global expansion efforts, made several executive hires and acquired leading digital health company HealthLoop to catalyze growth in the ambulatory space.

2018 Global Digital Health 100 – emocha included

Explore the 2018 Global Digital Health 100.

The Global Digital Health 100 is one of the HealthTech industries foremost technology awards programmes, celebrating innovation and entrepreneurship. It recognises and supports health technology companies that are demonstrating the greatest potential to change the way that healthcare is delivered.

Rexahn Receives Notice of Allowance for U.S. Patent Covering RX-3117 Use in a Broad Range of Tumor Types – Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 15/683,408, “Fluorocyclopentenylcytosine Methods of Use.” The patent application covers the use of RX-3117 in a broad range of tumor types that over-express UCK2, the enzyme that activates RX-3117. The company expects the patent to be issued within a few months from the notice of allowance and provide protection to 2036.

Viela Bio, NextCure among Maryland companies that received most VC funding in 2018. – Baltimore Business Journal

The top company received more than $280 million VC funding in 2018.

Billion-dollar year: Maryland builds venture capital momentum with record-breaking 2018 – Baltimore Business Journal

Seven firms brought in over $30 million last year, and five raised more than $70 million in venture capital.

Q4 2018 I-270 Lab Market Report

The extremely active lab real estate market is a bell-weather for the upcoming hyper-competitive talent market. Based on the recent real estate transactions and related hiring forecasts, we estimate the range of new positions in the Maryland life sciences market to be between 1,150 to 2,300 new hires in 2019.

Infographic: Visualizing the Future of the Pharma Market

By 2050, there will be two billion people that are 60 years or older globally. Meanwhile, the amount of seniors (65+ years old) in the U.S. will double to 100 million by 2060.

MdBio Foundation changes name to Learning Undefeated amid national expansion – Technical.ly Baltimore

In a move to reflect the reach into more states it has gained in recent years, MdBio Foundation unveiled a rebrand as Learning Undefeated on Tuesday.

FITCI is a incubator and accelerator for science and technology-based business.

Community members gathered Wednesday night at Hood College’s Hodson Auditorium to celebrate Frederick Innovative Technology Center Inc.’s 15th anniversary.

VitusVet, eying growth, hires OrderUp cofounder as COO – Technical.ly Baltimore

Like a lot of medical practices, veterinarians seek to send patients a message when they’re due for a check-up, schedule appointments and keep track of medical records. Yet Marc Olcott sees a lot of those tasks still happening by phone or on paper, and thinks it should all be available digitally.

Here are this year’s 20 most promising startups in Baltimore: realLIST 2019 – Technical.ly Baltimore

For the people looking to move within a thriving tech community, it’s important to be able to easily call upon the key players.

Equity Crowdfunding for Biotech Startups: Does it Work?

In the last decade, crowdfunding has become a popular way to finance all sorts of projects and products. Biotech is no exception, but many question whether the high risk and long term nature of investing in the biotech industry makes it a good fit for equity crowdfunding.

Keiretsu Forum Mid-Atlantic Partners and CONNECTpreneur to Advance Innovation and Entrepreneurship – Press Release – Digital Journal

The premier investor network in the Mid-Atlantic has entered into a resource partnership. Keiretsu Forum Mid-Atlantic and the CONNECTpreneur community have entered into an agreement that will advance innovation, entrepreneurship, and investment in the region.

Lung Cancer May Be Sniffed Out Earlier with Graphene e-Nose

Lung cancer may not be the first thought that crosses the mind when talking about breathalyzer tests. But, what if lung cancer detection were as easy as breathing into a device? That is the goal of a group of researchers from the University of Exeter who have recently taken a new approach to e-nose technology integrated with multi-layered graphene for early detection of lung cancer.

Accelerating Swiss innovations to market with strategic collaboration

Catalyze announces collaboration with Biopôle, providing dedicated services to members towards better access to non-dilutive funding opportunities.

Home | About BHI | BHI News | Programs | Partners | Contact

Copyright © BioHealth Innovation 2017
All Rights Reserved.

February 5, 2019

Love0

339th Edition – January 29, 2019

By adminBHI Weekly News Archives

BioHealth Innovation

If you are having trouble viewing this email, please click here

January 29, 2019

FOUNDING MEMBER OF

Win $ and Visibility in Front of Hundreds of Attendees at the 2019 BHCR Crab Trap

You thought the Shark Tank was tough…Wait until you enter the the BioHealth Capital Region Crab Trap!

Submit your application for the opportunity to present your innovation and be named the region’s early stage biohealth company with the most commercial potential at the 2019 BioHealth Regional Forum, $10,000, and MORE!

Application Deadline: March 1, 2019

Finalists will be announced: March 21st, 2019

Finalist Presentations BioHealth Capital Region Forum event: April 9th, 2019

Submit Application »

MaxCyte: Driving New Generation of Cell-Based Medicines – WXPress – Global open-access R&D enabling platform, life science industry news and perspectives

Cell therapy offers a treasure chest of new medicines, but there is still much to learn about cell activities and how to deliver these potential benefits before science and the industry can fully fulfill on their promise. One of cell therapy’s earliest pioneering companies is MaxCyte, based in Gaithersburg, MD and in the United Kingdom. Leading MaxCyte is president and CEO Doug Doerfler, a biotech pioneer who has more than 35 years of experience in the discovery, development, commercialization and international financing of biotechnology products and companies. He was also a founder of MaxCyte in July 1998.

Emocha wants to help Type 2 diabetes patients stick to their drug regimens

This new program is specifically aimed at helping patients with Type 2 diabetes, who take medications to control their blood sugar levels.

United Therapeutics Announces Closing Of License Agreement With Arena Pharmaceuticals For Ralinepag

United Therapeutics Corporation (Nasdaq: UTHR) today announced the closing of the transactions contemplated by its license agreement with Arena Pharmaceuticals, Inc. (Nasdaq: ARNA). Under the agreement, United Therapeutics acquired exclusive, worldwide rights to develop and manufacture the Phase 3 investigational drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension (PAH). Upon closing, United Therapeutics paid Arena $800 million. Arena is also entitled to potential milestone payments of up to $400 million based on the achievement of certain regulatory events as well as low double-digit tiered royalties on annual net sales of ralinepag products.

SBIR and Other Non-Dilutive Funding Sources – February 28

HOLD THE DATE – February 28, 2019 8 am. – 3:00 p.m.

Meet 1:1 with SBIR program managers. Learn more about their funding programs (SBIR and more!)

8-8:30 Networking and Registration

8:30 – 12:00 p.m. – Program Overviews

12:00 p.m. – 1:00 p.m. – Networking Lunch

1:00 p.m. – 3:00 p.m – 1:1 Meetings with Program Managers*

Agencies represented include: NSF, NIH NIA, NIH NCI, NIH NHLBI, NIH NIDA, US Army (invited)

*The program overview will be available by videoconference.

**You do not have to participate in 1:1 meetings. However, to do so, you must attend the overview session in person.PRE-REGISTRATION IS REQUIRED: RSVP by noon 2/26: BHI@BioHealthInnovation.org

Well Doc’s BlueStar highlighted on Forbes’ list of Digital Healthcare Growth Drivers

The digital transformation of healthcare will see significant growth in the next 12 months fueled by institutional interest in driving down costs and improving patient engagement. Expect increased pharma investment, improving regulatory status, payer engagement with digital tools and better telemedicine connectivity through consolidation.

Maryland E-Nnovation initiative provides matching funds for tech-focused research endowments – Technical.ly Baltimore

Four Maryland colleges are expanding tech-focused programming with funding from a state program.

The Maryland E-Nnovation Initiative Fund was created to spur research in scientific and technical fields at colleges and universities in the state.

Report: Most investment in DC-area cybersecurity startups goes to Maryland, Virginia – Technical.ly DC

Washington, D.C.–based cybersecurity investment firm Strategic Cyber Ventures released its first annual report on The State of 2018 Cybersecurity Investing that includes some key findings about the DMV.

GCTCI: Washington DC ranked as the top city globally for talent competitiveness

Washington, D.C. has been crowned as the city that’s leading the way in talent competitiveness, thanks to its ability to attract and nurture entrepreneurs, whilst meeting the needs of being a strongly-connected, “global” city.

Scoop: GSK’s venture team at SR One in talks to spin off from its big pharma founder, now under new R&D management – Endpoints News

The partners at SR One, a storied corporate biotech VC with investments across a wide range of drug developers on both sides of the Atlantic, are engaged in talks to split away from the pharma giant GlaxoSmithKline, according to sources familiar with a move that’s been in the works since at least late last year.

Education Top Budget Priority For Maryland With Record Funding For 2020 – CBS Baltimore

Gov. Hogan’s new fiscal 2020 budget is officially on the table, and it’s getting a preliminary thumbs up from the Democratic leadership in the General Assembly.

This year’s budget may go above and beyond when it comes to kids.

gel-e Expands Patent Estate with Next Level of Exclusivity

gel-e Inc., announces the issuance of United States Patent Number 10,179,145 by the U.S. Patent and Trademark Office, which broadly claims and discloses uses of the Company’s core technology.

Over-regulating drugs threatens Md. Life sciences industry – Baltimore Sun

One major focus for legislators during this year’s session is how to bring down the cost of health care, as everyday Marylanders struggle to afford the cost they pay at the pharmacy counter. Despite disagreements between different groups within and beyond health care, there is broad consensus that something must be done about the cost patients pay without denying Marylanders the world-class treatments available to them, many of which are made right here in Maryland.

Demystifying industry–academia collaboration

The past decade has seen intensified research collaboration between pharmaceutical companies and academic institutions. Although such partnerships are recognized as a source of innovation and a key pillar to advance science in drug discovery, they are replete with challenges. Despite much anecdotal evidence and debate, fact-based evidence on the nature of these challenges and how to manage them is scarce.

The State of Health Care Innovation in 2019: The World Awaits – LinkedIn

2019 has kicked off with a wave of innovative health care solutions highlighted at mega-conferences like CES and the J.P. Morgan Healthcare Conference – from the introduction of the first wearable blood pressure monitor to virtual home health care for seniors to online vision tests allowing patients to renew prescriptions from anywhere at anytime. We are truly living through an age of disruption spurred by technological advances.

10 Takeover Targets to Watch in 2019

After weeks of speculation that biopharma deal making would cool off, 2019 got off to a flying start as far as mergers-and-acquisitions (M&A) is concerned, thanks to two blockbuster transactions: Bristol-Myers Squibb’s planned $74 billion acquisition of Celgene, followed four days later by Eli Lilly’s planned $8 billion purchase of Loxo Oncology—a deal that quickly became the buzz of the J.P. Morgan 37th Healthcare Conference, held earlier this month in San Francisco.

Spring 2019 NCI-UMD Partnership for Integrative Cancer Research Symposium

Our National Cancer Institute-University of Maryland (NCI-UMD) Partnership for Integrative Cancer Research reflects the broad interests of our participating NCI and UMD researchers. We are delighted to invite you to our annual NCI-UMD Partnership for Integrative Cancer Research Symposium on Friday, February 8th from 10am-4pm which will take place in Bethesda, Maryland in the John Edward Porter Neuroscience Research Center at the National Institutes of Health, Bldg 35A, Room 620/630. Please register and plan to participate in our October symposium. The final agenda will be announced shortly.

Jonathan Aberman: Why are we using Silicon Valley’s entrepreneurship model? – Washington Business Journal

We need to chart a new course.

Diet, the Gut Microbiome, and Colorectal Cancer: Are They Linked?

Colorectal cancer (CRC) is one of the leading causes of death in the western society, being ranked third most lethal neoplasia in the United States in both men and women.1 In 2014, the American Cancer Society estimated that approximately 136,830 new cases of CRC will be diagnosed in the United States, with more than 50,000 Americans expected to die due to disease progression or complications.1,2 The lifetime cancer-related costs are considerable and differ by cancer site, disease stage, age at diagnosis, and treatment phase. Considering direct healthcare costs, CRC is the second most important neoplasia with estimated expenses of more than $14 billion.3,4

Deloitte named world’s most valuable professional services brand | Deloitte China | Newsroom

Deloitte has surpassed its peers to become the world’s most valuable professional services brand, according to the 2019 Global 500 report issued by Brand Finance on 22 January 2019. Deloitte’s strong performance was due to higher scores in Brand Finance’s metrics of familiarity, consideration, satisfaction, preference, recommendation and revenue.

First CRISPR Clinical Trial Begins in Europe | Scienceline

The highly touted gene-editing technology CRISPR is facing one of its first real-world tests. As many as 12 patients who live with the blood disorders sickle cell anemia or beta-thalassemia have started enrolling in a Europe-based clinical trial that may serve as an early indicator of whether gene editing will live up to the hype.

Home | About BHI | BHI News | Programs | Partners | Contact

Copyright © BioHealth Innovation 2017
All Rights Reserved.

February 5, 2019

Love0

338th Edition – January 22, 2019

By adminBHI Weekly News Archives

BioHealth Innovation

If you are having trouble viewing this email, please click here

January 22, 2019

FOUNDING MEMBER OF

William E. Bentley, Professor of Engineering and Founding Director of the Fischell Institute for Biomedical Devices joins Rich Bendis for the first BioTalk of 2019

William E. Bentley is the Robert E. Fischell Distinguished Chair of Engineering and the Inaugural Director of the Robert E. Fischell Institute for Biomedical Devices. He is appointed in the Fischell Department of Bioengineering as well as the Department of Chemical and Biomolecular Engineering at the University of Maryland, College Park and the Institute for Bioscience and Biotechnology Research. At Maryland since 1989, Dr. Bentley has focused his research on the development of molecular tools that facilitate the expression of biologically active proteins and on materials incorporated into biomedical devices, having authored over 300 related archival publications

He is a fellow of AAAS, ACS, AIMBE, and the American Academy of Microbiology. He has served on advisory committees for the NIH, NSF, DOD, DOE, FDA, USDA, and several state agencies and has mentored over 40 PhDs and 25 postdocs, many now in leadership roles within industry (24), federal agencies (5) and academia (26). He co-founded a protein manufacturing company, Chesapeake PERL, based on insect larvae as mini bioreactors.

Listen now on iTunes , Google Play , and TuneIn.

Viela Bio on BioSpace Top 20 Life Sciences Companies to Watch

BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.

Alexandria and NEA Number 1 and 2 in List of VC Firms That Made the Most Investments in Healthcare Startups in 2018

To those who have been following the space, it’s no surprise that 2018 has been a record year for venture capital investing in healthcare. With $28.8 billion raised through the end of November (and big deals like the $400 million Series C raised by Relay Therapeutics last week) startups in the sector have raised more money this year than any year before in the last 10 years that VC funding database Pitchbook has tracked investments in the space.

Lupin receives FDA approval for Levothyroxine Sodium Tablets USP – Lupin

Pharma major Lupin announced that it has received approval for its Levothyroxine Sodium Tablets USP, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, and 300 mcg from the United States Food and Drug Administration (FDA) to market a generic version of AbbVie, Inc’s Synthroid Tablets, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, and 300 mcg.

Maryland’s Vitus Vet #1 App for Pet Owners

There’s an app for everything these days — including a plethora for people with pets.

Thanks to the streamlined design of most current apps, you don’t have to be technically savvy to know how to download and use them on your smartphones or tablets.

Tax Implications and Accounting Issues for Start-Ups — January 23rd

Join us for the January 23, 2019 for PATHFINDER INNOVATION PROGRAM

Learn more about:

Overview and Reporting Requirements for Type of Entity
Impact of Accounting Methods
Start-up Company Issues
International Investment
Tax Law Changes
State Tax Concerns
Tax Planning

Schedule

12:00 p.m – Networking Lunch

12:30 – 1:30 p.m. – Discussion with Q&A* – Tom Christiana, Partner – Aronson, LLC

1:30 – 4:00 p.m. – One-on-one Meetings**

RSVP by noon, January 22, at BHI@BioHealthInnovation.org

No charge to attend but pre-registration is required.*Attend in person (1 Church St, Rockville) or by videoconference**Attendance at discussion is required to participate in 1:1

Download Flyer »

Alexandria Real Estate buys Jazz Pharmaceuticals-leased Stanford Research Park building at 3170 Porter Drive – Silicon Valley Business Journal

Biotech landlord and developer Alexandria Real Estate Equities has purchased an office complex in Palo Alto’s Stanford Research Park from Stanford University for $100.3 million.

Maryland companies raised more than $1B in venture funding in 2018 – Technical.ly Baltimore

Maryland’s overall venture capital haul for 2018 totaled crossed the billion-dollar mark for the first time since 2001, according to the PwC/CB Insights MoneyTree report.

MCEDC Welcomes Bill Tompkins — MCEDC

The Montgomery County Economic Development Corporation (MCEDC) and its board are pleased to welcome Bill Tompkins as Chief Operating Officer. Bill brings to Montgomery County a strong corporate and trade association background, having served in multiple senior level roles for Fortune 500 and other organizations.

Johns Hopkins, health tech Emocha win CDC funding to study effect of financial incentives on addiction recovery – Baltimore Business Journal

Study participants will use emocha’s platform to video record themselves each day for 24 weeks as they take buprenorphine.

Maryland ranks No. 3 for contribution to tech economy – Baltimore Business Journal

Milken Institute publishes its 2018 State Technology and Science Index.

Popper and Company Adds Diagnostic Industry Leaders as Senior Advisors

Popper and Co., a strategy consulting and transaction advisory firm guiding medical technology and life sciences companies working on the leading-edge of diagnostics and patient management, announced today the addition of Vincent Linder, PhD and Gene Vivino to its growing team of industry and clinical senior advisors. Both Dr. Linder and Mr. Vivino provide strong industry knowledge and extensive operating experience, in addition to broad networks in both Europe and Asia.

Small Business Network: Making Montgomery County Business Friendlier – YouTube

Montgomery County Executive Marc Elrich and Council President Nancy Navarro are the guests of Montgomery Community Media’s January Small Business Network (SBN) session.

Well Doc’s BlueStar highlighted on Forbes’ list of Digital Healthcare Growth Drivers

The digital transformation of healthcare will see significant growth in the next 12 months fueled by institutional interest in driving down costs and improving patient engagement. Expect increased pharma investment, improving regulatory status, payer engagement with digital tools and better telemedicine connectivity through consolidation.

Protenus to expand, move HQ to Brown’s Wharf in Fells Point – Baltimore Business Journal

The health data security company has outgrown its offices near Little Italy.

Maryland universities propose new programs – Maryland Daily Record

Maryland universities are creating new academic programs they say could help the state adapt to a changing innovation economy and help meet needs for tomorrow’s educators. The Education Policy and Student Life committee of the University System of Maryland’s Board of Regents moved forward this week with eight new programs proposed from system universities.

Hopkins researchers to study whether financial rewards, video monitoring can help opioid addiction treatment – Baltimore Sun

Researchers at the Johns Hopkins University School of Medicine have been awarded $2.1 million by the U.S. Centers for Disease Control and Prevention to study whether paying patients to take their medicine and tracking their doses with video software can help patients stick with their treatment for opioid addiction.

Economic Alliance of Greater Baltimore taps Michele Whelley as new CEO – Baltimore Business Journal

The hire is well known in the business community for her previous roles at local organizations.

Pappas Capital raises $85.8 mln for venture-capital fund – PE Hub

Pappas Capital has raised $85.8 million toward a venture-capital fund, according to a filing with the SEC.

A. M. Pappas Life Science Ventures V attracted capital from 29 LPs.

Attendees fed up with venue, high prices call to move JPM out of San Francisco | FierceBiotech

While the high cost of living in San Francisco has famously grabbed headlines, the costs of simply meeting there, even for a few days, are becoming untenable for some.

As 9,000 official badge holders—alongside what could feel like three times as many unofficial attendees—swarmed downtown San Francisco for the annual J.P. Morgan Healthcare Conference, much of the opening small talk in the hastily bedless hotel suites-turned-meeting rooms began with, “Can you believe some of these prices?”

BIO launches Innovature, a new platform to support innovation in food and agriculture

BIO, in partnership with the American Seed Trade Association (ASTA), is proud to announce today that we are launching Innovature, an initiative to engage people in a dialogue on the promise of innovation in food and agriculture and the tangible benefits it brings to our planet, our health, and our food.

The goal of Innovature is to grow awareness, acceptance and adoption of gene editing in food and agriculture, and seed positive ground for future innovations that address some of society’s most pressing challenges, such as climate change, hunger and sustainability.

For CAR-Ts to be successful, figuring out manufacturing is key – MedCity News

To date, the conversation around CAR-T cell therapies in cancers has focused on the most visible considerations: efficacy, toxicity and cost. But while those factors are important, another one deserves equal consideration: manufacturing.

Press Announcements > Statement from FDA Commissioner Scott Gottlieb, M.D. and Peter Marks, M.D., Ph.D., Director of the Center for Biologics Evaluation and Research on new policies to advance development of safe and effective cell and gene therapies

The FDA is witnessing a surge of cell and gene therapy products entering early development, evidenced by a large upswing in the number of investigational new drug (IND) applications. Based on this activity, we anticipate that the number of product approvals for cell and gene therapies will grow in the coming years, reflecting significant scientific advancement and the clinical promise of these new innovations.

Frederick’s diversified life sciences and bio industry | Maryland Business News

Without a doubt, Frederick’s life sciences and biotechnology industry is closing out the year with strong growth, and starting 2019 with a solid foundation built on numerous innovative organizations and several areas of expertise.

BRCA Exchange aggregates data on thousands of BRCA variants to inform understanding of cancer risk | National Institutes of Health (NIH)

A global resource that includes data on thousands of inherited variants in the BRCA1 and BRCA2 genes is available to the public. The BRCA Exchange was created through the BRCA Challenge, a long-term demonstration project initiated by the Global Alliance for Genomics and Health (GA4GH) to enhance sharing of BRCA1 and BRCA2 data. The resource, available through a website and a new smartphone app, allows clinicians to review expert classifications of variants in these major cancer predisposition genes as part of their individual assessment of complex questions related to cancer prevention, screening, and intervention for high-risk patients.

Why gene therapies don’t work for everyone

Growing up in Devon in the 1980s, brothers James* and Matt* had to be careful with their antics–a cut or bruise could land them in hospital.

New Clinical Trial Aims To Detect Cancer With A Quick Breathalyzer Test

Nowadays ‘liquid biopsies,’ the notion of detecting cancer using only a blood test to detect minute amounts of circulating tumor are fairly well-known. But what if not even a blood test was needed to detect cancer, merely a few lungfuls of air?

Home | About BHI | BHI News | Programs | Partners | Contact

Copyright © BioHealth Innovation 2017
All Rights Reserved.

January 28, 2019

Love0

337th Edition – January 15, 2019

By adminBHI Weekly News Archives

BioHealth Innovation

If you are having trouble viewing this email, please click here

January 15, 2019

FOUNDING MEMBER OF

BHI Names Healthcare Innovation Expert John Sullivan as New Entrepreneur-in-Residence for National Institutes of Health

BioHealth Innovation, Inc. (BHI) announced today that John P. Sullivan has joined BHI as a new Entrepreneur-in-Residence (EIR) for the National Institutes of Health (NIH), working with Ethel Rubin, PhD, ventures team head, to provide product, corporate and private investment strategy for NIH portfolio companies.

“We are pleased to have Mr. Sullivan join the team of EIRs serving NIH,” said Richard Bendis, BHI President and CEO. “His expertise in building, operating and acquiring health technology businesses will certainly be an asset as he works to provide the institution with industry insights and commercialization perspectives.”

Established with NIH in 2012, the EIR program is designed to connect NIH-funded start-ups with experienced industry experts who can help them maneuver through multi-disciplinary technical challenges and the business and regulatory environment to deploy new healthcare and biomedical technologies.

Autolus to create 170 jobs, invest $28M in new Rockville HQ – Baltimore Business Journal

Montgomery beat out Boston and the Philadelphia areas to win the project.

Open for Business! 1800+ BioHealth Jobs in Region

A sign of the BioHealth Capital Region’s industry growth is the increase in hiring taking place throughout the region. More than 1800 job opportunities are listed on BioHealth Innovation’s website (www.BioHealthInnovation.org/Jobs). Many with relatively young companies expanding their regulatory, manufacturing and R&D teams. To post positions, Email: BHI@BioHealthInnovation.org.

GSK: Advancing Global Vaccines from its Rockville campus – Success Stories — MCEDC

GlaxoSmithKline – Advancing the science of vaccines and improving lives around the world.

No stethoscope for pain: Scientists seek real way to measure

Is the pain stabbing or burning? On a scale from 1 to 10, is it a 6 or an 8?

Over and over, 17-year-old Sarah Taylor struggled to make doctors understand her sometimes debilitating levels of pain, first from joint-damaging childhood arthritis and then from fibromyalgia.

Autolus Therapeutics Enters Lease with Alexandria Real Estate Equities, Inc. for Future Commercial-Scale Manufacturing Site and U.S. Headquarters

Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has signed a long-term, full-building lease with Alexandria Real Estate Equities, Inc. (NYSE: ARE) for the construction and development of an 85,000 square foot build-to-suit facility to be located in the Shady Grove Life Sciences Center in Rockville, Maryland. The new facility will house offices for Autolus’ U.S.-based research and development, commercial and corporate functions and serve as its first full commercial-scale manufacturing center, with a planned capacity to produce 5,000 T cell therapies annually. In addition, Autolus has established a temporary U.S. headquarters in Rockville until the new facility is ready for occupancy, which is currently expected to occur in 2021.

Tax Implications and Accounting Issues for Start-Ups – January 23rd

Join us for the January 23, 2019 for PATHFINDER INNOVATION PROGRAM

Learn more about:

Overview and Reporting Requirements for Type of Entity
Impact of Accounting Methods
Start-up Company Issues
International Investment
Tax Law Changes
State Tax Concerns
Tax Planning

Schedule

12:00 p.m – Networking Lunch

12:30 – 1:30 p.m. – Discussion with Q&A* – Tom Christiana, Partner – Aronson, LLC

1:30 – 4:00 p.m. – One-on-one Meetings**

RSVP by noon, January 22, at BHI@BioHealthInnovation.org

No charge to attend but pre-registration is required.

*Attend in person (1 Church St, Rockville) or by videoconference

**Attendance at discussion is required to participate in 1:1

Download Flyer »

SBIR and Other Non-Dilutive Funding Sources – January 29th

HOLD THE DATE – January 29, 2019 8 am. – 12:30 p.m.

Meet 1:1 with SBIR program managers. Learn more about their funding programs (SBIR and more!)

8-8:30 Networking and Registration

8:30 – 10:00 a.m. – Program Overviews*

10:00 – 12:30 p.m. – 1:1 Meetings with Program Managers**

Agencies represented include: NSF, NIH NIA, NIH NCATS, NIH NCI, NIH NHLBI, NIH NIDA, US Army (invited)

*The program overview will be available by videoconference.

**You do not have to participate in 1:1 meetings. However, to do so, you must attend the overview session in person.PRE-REGISTRATION IS REQUIRED: RSVP by noon 1/27: BHI@BioHealthInnovation.org

Johns Hopkins Technology Ventures Leadership Update from Christy Wyskiel

Please join me in celebrating two exciting leadership changes at JHTV. Steve Kousouris, who has been serving as Interim Executive Director of Technology Transfer at JHTV since June, has assumed this role permanently effective Jan.1. Additionally, Mark Bailey, previously Associate Director of Finance, will assume responsibility for the portfolio that Steve has overseen since 2013 in the capacity of Director, Finance & Administration.

World’s Top 50 Universities For Computer Science Degrees, 2019 – Johns Hopkins and University of Maryland listed

MOVE over Caltech, Georgia Tech, and MIT – the University of Oxford has been named the best university in the world for computer science degrees for 2019. The ranking compares the top computer science programs in the world. ETH Zurich ranked number 2 on the list, followed by Stanford University (No. 3), the University of Cambridge (No. 4), and Massachusetts Institute of Technology (No. 5).

FDA plans to create a new office to leverage cutting-edge science – STAT

The Food and Drug Administration plans to create a new office to improve the review of new medicines — one that will develop a standardized approach to using personalized medicine, digital data, and patients’ own reports, according to Commissioner Scott Gottlieb.

Top 10 Global Biopharma IPOs of 2018

2018 was a record year for biopharma initial public offerings (IPOs), with an all-time high of $6.3 billion raised by 58 U.S. companies as of December 17, according to Renaissance Capital, compared with 36 companies garnering some $4 billion in 2017.

Why pharma is starting to think more like Amazon – MedCity News

Pharmaceutical companies are starting to see the retail supply chain as more than just a way to get drugs from point A to point B. It can be an opportunity to ensure better products and services and create a competitive advantage with consumers – but only if data is connected and well managed.

Baltimore’s b.well Connected Health honored as ‘Top Innovator’ at Accenture’s global health startup competition – Technical.ly Baltimore

A pair of Baltimore-based digital health startups were among the award winners at the conclusion of the Accenture HealthTech Innovation Challenge this week.

Precision medicine is “not at loggerheads” with population health – MedCity News

Precision medicine is using knowledge about a person’s genetic code to tailor treatments to that individual for the most optimal outcome. Think of sequencing tumors and then determining a treatment regimen based on biomarkers or genetic variants.

2018 New Drugs Approvals: An All-Time Record, And A Watershed

For months, it had been clear that 2018 would be a banner year for pharmaceutical innovation. The question was, by how much would it shatter the previous (1996) record of 50 approvals (excluding diagnostics and imaging agents)? We now know. It exceeded it by over 20 percent. Last year, U.S. regulators approved a total of 61 drugs – 59 by FDA’s Center for Drug Evaluation and Research (CDER), plus two recombinant therapies (Andexxa and Jivi) by its Center for Biologics Evaluation and Research (CBER).

NJBIA Releases Indicators of Innovation Report – Insider NJ

Indicators of Innovation, a report issued today by the New Jersey Business & Industry Association, shows New Jersey at a challenging crossroads in its efforts to reclaim itself as the “Innovation State.”

JPMorgan Conference Is So Packed Attendees Meet in the Bathroom – Bloomberg

Brianna Wronko has an engineering degree from an Ivy League school and is the CEO of a health-care diagnostics company. Until this week, she never thought she’d be stuck holding business meetings in a San Francisco hotel bathroom.

Home | About BHI | BHI News | Programs | Partners | Contact

Copyright © BioHealth Innovation 2017
All Rights Reserved.

January 28, 2019

Love0

Previous 1 … 27 28 29 30 31 … 62 Next

© 2025 BioHealth Innovation.